Key Insights

Highlights

Success Rate

84% trial completion

Published Results

406 trials with published results (13%)

Research Maturity

1533 completed trials (49% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

9.1%

282 terminated out of 3102 trials

Success Rate

84.5%

-2.1% vs benchmark

Late-Stage Pipeline

7%

218 trials in Phase 3/4

Results Transparency

26%

406 of 1533 completed with results

Key Signals

406 with results84% success282 terminated

Data Visualizations

Phase Distribution

2,196Total
Not Applicable (854)
Early P 1 (34)
P 1 (456)
P 2 (634)
P 3 (184)
P 4 (34)

Trial Status

Completed1,533
Unknown472
Recruiting435
Terminated282
Active Not Recruiting137
Withdrawn113

Trial Success Rate

84.5%

Benchmark: 86.5%

Based on 1533 completed trials

Clinical Trials (3103)

Showing 20 of 20 trials
NCT04093167Phase 2Active Not RecruitingPrimary

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

NCT05715255Not ApplicableActive Not Recruiting

Adaptive Symptom Self-Management Immunotherapy Study

NCT07646847Not ApplicableRecruiting

A Study of a Side Effects and Resource Navigation Program for People With Cancer

NCT07740239Recruiting

A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial

NCT06540196Not ApplicableRecruitingPrimary

The Development, Safety, and Feasibility of an Artificial Intelligence-Powered Platform (NodeAI) for Real-Time Prediction of Mediastinal Lymph Node Malignancy During Endobronchial Ultrasound Staging for Lung Cancer

NCT06410300RecruitingPrimary

Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

NCT05632809Phase 2RecruitingPrimary

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

NCT04736173Phase 2Active Not Recruiting

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

NCT07732686Not Yet Recruiting

Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry

NCT06863623Not ApplicableCompletedPrimary

The Effect of Immersive Virtual Reality and Relaxing Videos on Lung Cancer Patients

NCT07008664RecruitingPrimary

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer

NCT00034216Recruiting

Collection of Blood From Patients With Cancer

NCT01441089Recruiting

Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

NCT06644768Phase 1Active Not Recruiting

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

NCT00340405CompletedPrimary

Development of a Biologic Specimen Bank for the Study of Early Markers of Lung Cancer Among Tin Miners in Yunnan, China

NCT07630168Phase 2Not Yet RecruitingPrimary

Effects of Infusion Timing on Treatment Response in Solid Tumors

NCT03693014Phase 2Active Not Recruiting

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

NCT06910657Phase 1Recruiting

IDOV-Immune for Advanced Solid Tumors

NCT06618287Phase 1RecruitingPrimary

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT05456841Not ApplicableRecruitingPrimary

Empathic Communication Skills (ECS) Training

Scroll to load more

Research Network

Activity Timeline